All News

#RA pts on #baricitinib less likely to discontinue treatment & more likely to achieve remission than pts receiving biologic /other tsDMARD. 👉🏼Results from RA-BE-REAL observational study 👉🏼Bari(2 or 4mg) vs biologic/other tsDMARD Abs#1223 #ACR21 @RheumNow https://t.co/WRN1OCX9Bq https://t.co/UCFF6hAY7G

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
In 🇦🇺 we're delighted to be working with @Sarah_L_Mackie et al on the STERLING-PMR trial: - relapsing PMR - pragmatic RCT - MTX (alt LEF) 🇬🇧 @NIHRresearch @LeedsBRC @profbdasgupta @DrMaxYates1 et al 🇦🇺 @nhmrc @CatherineL_Hill @helenkeen73 @drceowen #ACR21 PMR/GCA SG @RheumNow https://t.co/YtnPpHxNqz
David Liew drdavidliew ( View Tweet)
Peripheral and axSpA pts with low Vitamin D levels (<30) had worse disease activity and functional impairment (BASDAI, ASDAS, BASFI) compared to pts with normal Vit D levels. Abs#1316 #ACR21 @RheumNow https://t.co/ulIqOAnWtp https://t.co/aMQaTpduJK

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
@Sineadm15 @bososhea on undiagnosed depression in axSpA. Common, and associated with worse disease activity and quality of life. Abstr#1305 #ACR21 @RheumNow https://t.co/PBH1F3XEGv
Richard Conway RichardPAConway ( View Tweet)
#ACR21 Abs#1224. ⬇️ CD39 expression on B cell predicts occurrence of anti-drug Ab in RA on RTX ⭐️13/23 pts on RTX became ADAb+. No diff in concomitant MTX usage ⭐️Baseline CD73 similar, but lower CD39 predictive of ADAb https://t.co/QzbAmXtTmZ @Rheumnow https://t.co/CLtEev69YD

Links:

Eric Dein ericdeinmd ( View Tweet)
Minimal disease activity achievement in PsA achieved by 22.8% in 6 mo of b/ts DMARD MDA achievers were: ➡️Younger ➡️🔽 Disease duration; ➡️ Male ➡️Non-obese ➡️bDMARD-naïve at baseline ➡️🔼 probability achieving MDA components➕MCID PROMs at 6 mo Abst# 1344 #ACR21 @Rheumnow

swethaann23 swethaann23 ( View Tweet)

Effect of BMI on PRO treatment response in PsA. Increasing BMI associated with lower response. More pronounced in TNFi than IL-17 or JAKi. Abstr#1327 #ACR21 @RheumNow https://t.co/qhgVlW72uM
Richard Conway RichardPAConway ( View Tweet)
In this study, ⭕AS pts w/>=2 #comorbidities were associated w/ poorer outcome measures after 2 yrs of ffup vs. pts w/ no comorbids ⭕Pts w/ >=2 comorbids were likely to dc 1st anti-TNF Address comorbidities, ⬆ chances of better outcomes & QoL @RheumNow #ACR21 abs1309 https://t.co/sTnjaC1a1l
sheila RHEUMarampa ( View Tweet)
#ACR21 Abs#1225: B/L Extracell Matrix Biomarkers predict ABA response in MTX-naive, +ACPA early RA ⭐️ECM biomarkers predict SDAI remission or DAS28 w ABA+MTX vs PBO+MTX. ⭐️⬆️CTX1 biomarker predicts efficacy endpts for ABA+MTX https://t.co/7wHQefb5D4 @Rheumnow

Links:

Eric Dein ericdeinmd ( View Tweet)

Wk 12 disease activity predicts wk 24/26 remission/low disease activity with #upadacitinib 15mg in MTX-naïve or inadequate responders to MTX and/or TNFi pts. ≥50% improvement in SJC/TJC at Wk 12 was assoc with wk 24/26 remission/low disease activity. Abs#1237 #ACR21 @RheumNow https://t.co/PAaCe5MAcu
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 - Starting soon - The Gift of Gab! with @BayviewMedicine @jhrheumatology Jason Liebowitz moderating Communication for the Physician with @Wharton Janet Zeide. Learn about the RHEUM acronym for speaking! @Rheumnow https://t.co/wcgFUBcZeX
Eric Dein ericdeinmd ( View Tweet)
EULAR update on vaccines. HZ vaccine safe with csDMARDs and TNFα blockers. Reduced cell immune response after 1 year. Assess Varicella Abs if exposure unknown. Non-live recombinant subunit adjuvant zoster vaccine may be a game changer @RheumNow #ACR21 8M101 https://t.co/PTLqYGRIGf
Dr. Antoni Chan synovialjoints ( View Tweet)
Innovative! Self-home fetal heart rate monitoring by the mother is feasible, accurate, effective for those with +anti-Ro/SSA Ab. The study is still recruiting https://t.co/9BFihsgW5A Abst#1464 #ACR21 @rheumnow https://t.co/ggmOpSGdZk

Links:

TheDaoIndex KDAO2011 ( View Tweet)

RheumNow’s expanded coverage of #ACR21 is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

Abs#1036: illness-related uncertainty significantly correlates with #depression, #anxiety, and sickness impact in patients with autoimmune #rheumaticdiseases. Particularly strong associations with #AAV and #SSc. #MentalHealth #ACR21 @RheumNow https://t.co/SiV9fst3Bh https://t.co/w8VRQHdAJC

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
⚡️A new biomarker of structural progression in RA? Plasma levels of CXCL13 ⬆️ @ baseline vs. ctrl and ⬇️ (p< 0.0001) after 1 yr treatment in a eRA cohort. Levels above 85pg/ml ⬆️ x5 risk of > severe radiographic status at 11yrs. @RheumNow #ACR21 #Abst1204 https://t.co/LnkayR1YrY https://t.co/W0xsgGuUDW

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
#ACR21 Abst#1204. CXCL13 predicts long-term radiographic status in early RA ▶️ early RA has ⬆️ CXCL13, and ⬇️ w treatment ⭐️CXCL13 was best predictor of long-term radiographic destruction - better than DAS28CRP and CRP @Rheumnow https://t.co/ydYRbKMBZ2 https://t.co/qinEFb86Az

Links:

Eric Dein ericdeinmd ( View Tweet)
Increased risk of vertebral fractures in PsA pts OR 2.09 from meta-analysis and systematic review Abs#1304 #ACR21 @RheumNow https://t.co/0IazVBGHsF https://t.co/YrPMh1TZ6U

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
#ACR21 Abst#1229: Does BMI influence efficacy of SC (fixed dose) vs IV (body-wt adjusted) ABA in RA? ⭐️No difference between SC and IV ABA by BMI ⭐️BMI impacts response to ABA as >2nd line therapy and retention, but no difference bw dosing https://t.co/LqfZvLhBzU @Rheumnow

Links:

Eric Dein ericdeinmd ( View Tweet)

Is #calprotectin the new ESR/CRP? 👉🏼SLR finds calprotectin correlates w/ ultrasound synovitis in RA 👉🏼In some studies, it was a better biomarker than ESR/CRP 👉🏼It can distinguish ultrasound remission from subclinical synovitis Abs#1207 #ACR21 @RheumNow https://t.co/ADkRBq5KoG

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

×